The laboratory modern announced this Monday that the first volunteer of its clinical trial has already received a dose of its experimental vaccine of mRNA against HIV.
We recommend: Woman would have been cured of HIV thanks to a new treatment with stem cells
The open-label, multicenter, randomized phase 1 trial (HVTN 302) is designed to assess the safety and immunogenicity of the experimental HIV mRNA-1574 vaccines.
The leading hypothesis is that soluble, membrane-bound mRNA vaccines may be safe for HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to include about 100 seronegative adults between the ages of 18 and 55.
“It is gratifying to see that experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field. We are optimistic that this study will pave the way for further use of mRNA in HIV,” said Larry Corey, principal investigator for the HIV Vaccine Trials Network Leadership Operations Center.
ANNOUNCEMENT ?: We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1574, our experimental human immunodeficiency virus (#HIV) trimmer #mRNA #vaccine candidate. https://t.co/etMyVK1SoH pic.twitter.com/tNdwR8xZAK
— Modern (@moderna_tx) March 14, 2022
“Developing a vaccine that induces sustained protective levels of HIV-neutralizing antibodies in humans has been elusive. At Moderna, we believe that mRNA offers an opportunity to take a new approach to this challenge,” said Moderna President Stephen Hoge.
“With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple natively encoded HIV mRNA trimers and harness the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine. ”, he added.
The trial is sponsored and funded by the US National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS.
HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong progressive disease with no cure. About 38 million people globally are currently living with HIV.
Moderna is currently advancing two preventive HIV vaccine strategies. In addition to this trial, the laboratory is participating in testing of the HIV vaccine antigens, mRNA-1644 and mRNA-1644v2-Core, which are being evaluated in a Phase I trial sponsored by IAVI and the Bill & Melinda Foundation. Gates.
With information from Infosalus/Europa Press.